Additional file 1 of Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs

Autor: Tejaswini P. Reddy, Choi, Dong S., Anselme, Ann C., Qian, Wei, Chen, Wen, Lantto, Johan, Horak, Ivan D., Kragh, Michael, Chang, Jenny C., Rosato, Roberto R.

Additional file 1. Table 1. Description of the main characteristics of each PDX tumor line are presented including their triple negative (i.e. ER−, PR− and HER2−) status, and the positive expression of EGFR and HER3 in all of them, with the exc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::136cc68ce1922f22163ed306dc634009

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The ERβ4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERβ variants ERβ2 and ERβ5 increase aggressiveness of TNBC by regulation of hypoxic signaling.

Autor: Faria M; University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science & Engineering Research Center, Houston, Texas, USA., Karami S; University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science & Engineering Research Center, Houston, Texas, USA., Granados-Principal S; Department of Medical Oncology, Hospital of Jaen, Jaen, Spain., Dey P; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Verma A; Institute for Computational Biomedicine, Department of Physiology and Biophysics Weill Cornell Medicine, New York, NY, USA., Choi DS; Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas, USA., Elemento O; Institute for Computational Biomedicine, Department of Physiology and Biophysics Weill Cornell Medicine, New York, NY, USA., Bawa-Khalfe T; University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science & Engineering Research Center, Houston, Texas, USA., Chang JC; Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas, USA., Strom AM; University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science & Engineering Research Center, Houston, Texas, USA., Gustafsson JÅ; University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science & Engineering Research Center, Houston, Texas, USA.; Department of BioSciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.

Publikováno v: Oncotarget [Oncotarget] 2018 Jan 10; Vol. 9 (15), pp. 12201-12211. Date of Electronic Publication: 2018 Jan 10 (Print Publication: 2018).